期刊
CANCER LETTERS
卷 314, 期 2, 页码 176-184出版社
ELSEVIER IRELAND LTD
DOI: 10.1016/j.canlet.2011.09.026
关键词
Bone metastases; Breast cancer; Osteoclast; mTOR; Rapamycin
类别
资金
- Government of Quebec
- Lloyd Carr-Harris Fellowship
- McGill University
- Fonds de la recherche en sante du Quebec
- Cancer Research Society
Breast cancer metastasis to bone results in pain, pathological fractures and hypercalcemia. Activation of osteoclasts is critical for the formation of osteolytic lesions by metastasizing tumors. Although the potent drugs, zoledronic acid and Denosumab were introduced, the presence of resistant or intolerant cases necessitated the continued search of osteoclast-targeting treatments. Rapamycin acts through the mTOR pathway, which is important for osteoclast formation. Mouse mammary carcinoma 4T1 cells were injected into the tibia of balb/c mice. Rapamycin treatment significantly decreased the osteoclast population and osteolysis associated with experimental metastases. Our data indicate the benefit of rapamycin in treating metastases-associated osteolytic disease. (C) 2011 Elsevier Ireland Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据